July 8, 2009, Raleigh, NC –
Trio Clinical Research, a leading clinical research services company supporting the pharmaceutical, biotechnology and medical device industry announced today a relocation of the company’s headquarters. The relocation provides Trio with larger office space to accommodate the company’s growth, and more amenable facilities for staff and visiting customers.
Trio’s new headquarters office, with 14,000 square feet of space, is located at 8045 Arco Corporate Drive, Suite 200, Raleigh, North Carolina 27617. The new office is conveniently located in Brier Creek Corporate Center and is within five miles of Raleigh-Durham International airport.
“We are thrilled with the relocation of our headquarters office to a larger and more modern facility. This move is just one of several important initiatives positioning Trio as a comprehensive provider of clinical research services. Our new facility offers us an additional 3,000 square feet, affording not only additional office space for new employees, but also more upscale conference space for hosting client meetings,” said Betsy Brown, Chief Operating Officer of Trio Clinical Research.
Trio will be hosting an Open House reception for customers, contractors and local business leaders. Details of the event will be announced in the coming days.
About Trio Clinical Research
Trio Clinical Research is an innovative clinical research services company supporting the pharmaceutical, biotechnology and medical device industries in their quest to bring novel products to the market. Founded in 2003, Trio provides comprehensive clinical, functional outsourcing and resourcing services across a wide-range of therapeutic areas in phase I-IV clinical research. Trio’s extensive customer base includes a majority of the world’s top pharmaceutical and biotech companies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.